Yonkers
The LOX Get The Keys To Yonkers
HipHopWired Featured Video Source: Johnny Nunez / Getty After a universal waxing of Dipset at last week’s Verzuz battle in Madison Square Garden, The LOX’s hometown of Yonkers are so proud of them that they’ve decided to give the three-man group the keys to the city! Styles P took to his IG page to announce the exciting news and standing alongside Sheek Louch and Verzuz MVP, Jadakiss, Pinero let everyone know that the Lox would soon be “receiving the keys to the city,” but revealed that the ceremony would be more than just a symbolic gesture. “Even doper than that, we’re opening up a revised third park, a third workout station in Yonkers for people, kids, grownups, women and children to have family activities and keep focusing on your health.” Styles and the Lox out here trying to mak...
US election: Republicans hold back Democrats, narrowing path to Senate control
The battle for power in the Senate tightened into Wednesday as Democrats picked up a seat in Colorado, but suffered a setback in Alabama, and Republicans held their own in high-profile races in South Carolina, Iowa, Texas and Kansas, dramatically narrowing the political map. Republicans fought to retain their Senate majority by turning back a surge of Democrats challenging allies of President Donald Trump, and the Democrats’ various paths to seizing control were growing more limited. With several contests still too early to call, and one Georgia race heading to a January runoff, the final verdict is expected to drag on. Democrats gained a seat when ex-Gov. John Hickenlooper ousted GOP Sen. Cory Gardner in Colorado, a must-win to flip the Senate, but couldn’t hold on in Alabama, where forme...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
